FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890692389> ?p ?o ?g. }

• W2890692389 abstract "e14640 Background: Poly(ADP-ribose) polymerase (PARP) enzymes are involved in DNA repair and activated by DNA strand breaks. DNA damage from carboplatin is associated with activation of PARP. Preclinical data indicate that PARP inhibition and trapping potentiates the anti-tumor effect of platinum chemotherapy. Talazoparib (T) is an oral, selective PARP inhibitor. This phase I study combines T with carboplatin (C) and paclitaxel (P). Methods: Two dosing schedules are being investigated. C is administered on day 1 and P on days 1, 8, and 15 of a 21-day cycle. T (100-1000mcg) is dosed once daily for days 1-7 (schedule A) or days 1-3 (schedule B). Dose escalation is by 3+3 design. Patients (pts) must have tumor type that is expected to respond to C + P or have BRCA germline or somatic mutation and adequate organ function. After 4-6 cycles of combination therapy, pts may continue the combination, change to C and intermittent T without P or change to T alone. Each schedule will have a 6 pt dose expansion at the MTD. The dose level (DL) 1 for schedule B is the previously reported MTD from schedule A (T 250mcg with C AUC 6 + P 80mg/m 2 ). Results: Schedule B results are reported: 15 pts (median age 56 yrs [range 43-76]) have been enrolled. Primary malignancies include colorectal (4), pancreas (4), prostate (2), urothelial (2), and other (3). Dose was initiated at Schedule A MTD. DL2 (T 350mcg with C AUC 6 + P 80mg/m 2 ) exceeded the MTD with 2 of 6 pts experiencing hematologic dose limiting toxicities (DLTs). DL1 is the confirmed schedule B MTD. Dose expansion to 6 pts is ongoing. Of the 11 pts with measurable disease, 3 (27%) had PR and 5 (45%) had SD. Pts were on study a median of 10 weeks (range 5-36+). Most common grade 3/4 AEs include leukopenia (53%), neutropenia (47%), and anemia (47%). One grade 5 AE of intracranial hemorrhage occurred, possibly related to therapy in the setting of grade 3 thrombocytopenia and concern for CNS disease. Conclusions: The schedule B MTD and RP2D is T 250 mcg with C AUC 6 and P 80mg/m 2 . Data from the full dose expansion will be presented. This combination was tolerated with prolonged responses seen at lower dose T in combination with C+P. Clinical trial information: NCT02317874." @default.
• W2890692389 created "2018-09-27" @default.
• W2890692389 creator A5011486016 @default.
• W2890692389 creator A5030084075 @default.
• W2890692389 creator A5030653735 @default.
• W2890692389 creator A5030878684 @default.
• W2890692389 creator A5040571934 @default.
• W2890692389 creator A5043124894 @default.
• W2890692389 creator A5048331793 @default.
• W2890692389 creator A5050180604 @default.
• W2890692389 creator A5050917158 @default.
• W2890692389 creator A5053602981 @default.
• W2890692389 creator A5061916566 @default.
• W2890692389 creator A5061952019 @default.
• W2890692389 creator A5079638534 @default.
• W2890692389 creator A5081735541 @default.
• W2890692389 creator A5084695166 @default.
• W2890692389 creator A5091511322 @default.
• W2890692389 date "2019-05-20" @default.
• W2890692389 modified "2023-09-25" @default.
• W2890692389 title "NCI9782: A phase 1 study of talazoparib in combination with carboplatin and paclitaxel in patients with advanced solid tumors." @default.
• W2890692389 doi "https://doi.org/10.1200/jco.2019.37.15_suppl.e14640" @default.
• W2890692389 hasPublicationYear "2019" @default.
• W2890692389 type Work @default.
• W2890692389 sameAs 2890692389 @default.
• W2890692389 citedByCount "0" @default.
• W2890692389 crossrefType "journal-article" @default.
• W2890692389 hasAuthorship W2890692389A5011486016 @default.
• W2890692389 hasAuthorship W2890692389A5030084075 @default.
• W2890692389 hasAuthorship W2890692389A5030653735 @default.
• W2890692389 hasAuthorship W2890692389A5030878684 @default.
• W2890692389 hasAuthorship W2890692389A5040571934 @default.
• W2890692389 hasAuthorship W2890692389A5043124894 @default.
• W2890692389 hasAuthorship W2890692389A5048331793 @default.
• W2890692389 hasAuthorship W2890692389A5050180604 @default.
• W2890692389 hasAuthorship W2890692389A5050917158 @default.
• W2890692389 hasAuthorship W2890692389A5053602981 @default.
• W2890692389 hasAuthorship W2890692389A5061916566 @default.
• W2890692389 hasAuthorship W2890692389A5061952019 @default.
• W2890692389 hasAuthorship W2890692389A5079638534 @default.
• W2890692389 hasAuthorship W2890692389A5081735541 @default.
• W2890692389 hasAuthorship W2890692389A5084695166 @default.
• W2890692389 hasAuthorship W2890692389A5091511322 @default.
• W2890692389 hasConcept C121608353 @default.
• W2890692389 hasConcept C126322002 @default.
• W2890692389 hasConcept C143998085 @default.
• W2890692389 hasConcept C2775930923 @default.
• W2890692389 hasConcept C2776387010 @default.
• W2890692389 hasConcept C2776694085 @default.
• W2890692389 hasConcept C2777292972 @default.
• W2890692389 hasConcept C2778239845 @default.
• W2890692389 hasConcept C2781451048 @default.
• W2890692389 hasConcept C2993640289 @default.
• W2890692389 hasConcept C502942594 @default.
• W2890692389 hasConcept C530470458 @default.
• W2890692389 hasConcept C71924100 @default.
• W2890692389 hasConceptScore W2890692389C121608353 @default.
• W2890692389 hasConceptScore W2890692389C126322002 @default.
• W2890692389 hasConceptScore W2890692389C143998085 @default.
• W2890692389 hasConceptScore W2890692389C2775930923 @default.
• W2890692389 hasConceptScore W2890692389C2776387010 @default.
• W2890692389 hasConceptScore W2890692389C2776694085 @default.
• W2890692389 hasConceptScore W2890692389C2777292972 @default.
• W2890692389 hasConceptScore W2890692389C2778239845 @default.
• W2890692389 hasConceptScore W2890692389C2781451048 @default.
• W2890692389 hasConceptScore W2890692389C2993640289 @default.
• W2890692389 hasConceptScore W2890692389C502942594 @default.
• W2890692389 hasConceptScore W2890692389C530470458 @default.
• W2890692389 hasConceptScore W2890692389C71924100 @default.
• W2890692389 hasLocation W28906923891 @default.
• W2890692389 hasOpenAccess W2890692389 @default.
• W2890692389 hasPrimaryLocation W28906923891 @default.
• W2890692389 hasRelatedWork W2043860312 @default.
• W2890692389 hasRelatedWork W2049349244 @default.
• W2890692389 hasRelatedWork W2051089470 @default.
• W2890692389 hasRelatedWork W2093988174 @default.
• W2890692389 hasRelatedWork W2131874020 @default.
• W2890692389 hasRelatedWork W2165171208 @default.
• W2890692389 hasRelatedWork W2204987058 @default.
• W2890692389 hasRelatedWork W2247465456 @default.
• W2890692389 hasRelatedWork W2252897685 @default.
• W2890692389 hasRelatedWork W2563325853 @default.
• W2890692389 hasRelatedWork W2588341962 @default.
• W2890692389 hasRelatedWork W2594860415 @default.
• W2890692389 hasRelatedWork W2791819953 @default.
• W2890692389 hasRelatedWork W2883344686 @default.
• W2890692389 hasRelatedWork W2889230329 @default.
• W2890692389 hasRelatedWork W2958246612 @default.
• W2890692389 hasRelatedWork W2976982111 @default.
• W2890692389 hasRelatedWork W3013413945 @default.
• W2890692389 hasRelatedWork W3082967940 @default.
• W2890692389 hasRelatedWork W3103856512 @default.
• W2890692389 isParatext "false" @default.
• W2890692389 isRetracted "false" @default.
• W2890692389 magId "2890692389" @default.
• W2890692389 workType "article" @default.